Overall, these studies suggest that anti-CGRP/rec mAbs are less effective in CH than in migraine, which is likely due to differences in pathophysiology but also to suboptimal trial methodologies poorly adapted to the natural history of CH, as highlighted in the recently updated IHS guidelines for clinical trials in CH [129]. The gene discussed is CALCA; the disease is migraine disorder.